Relpax is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Relpax is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, relpax has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Relpax has also been shown to inhibit trigeminal nerve activity in the rat.
Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.